vs

Side-by-side financial comparison of HUTCHMED (China) Ltd (HCM) and LESAKA TECHNOLOGIES INC (LSAK). Click either name above to swap in a different company.

HUTCHMED (China) Ltd is the larger business by last-quarter revenue ($270.8M vs $178.7M, roughly 1.5× LESAKA TECHNOLOGIES INC). LESAKA TECHNOLOGIES INC runs the higher net margin — 2.0% vs 0.7%, a 1.3% gap on every dollar of revenue. On growth, LESAKA TECHNOLOGIES INC posted the faster year-over-year revenue change (1.4% vs -16.5%). HUTCHMED (China) Ltd produced more free cash flow last quarter ($3.4M vs $-14.8M).

HUTCHMED (China) Ltd is a biopharmaceutical firm focused on discovering, developing and commercializing targeted and immunotherapies for oncology and immunological diseases. It operates across China and global markets, with multiple marketed oncology drugs and a robust pipeline of late-stage clinical candidates addressing unmet patient needs.

Lesaka Technologies is a South-African financial technology company that is listed on the NASDAQ and Johannesburg Stock Exchange. Lesaka’s primary focus is on financial inclusion, offering financial services to previously underserved communities and merchants.

HCM vs LSAK — Head-to-Head

Bigger by revenue
HCM
HCM
1.5× larger
HCM
$270.8M
$178.7M
LSAK
Growing faster (revenue YoY)
LSAK
LSAK
+18.0% gap
LSAK
1.4%
-16.5%
HCM
Higher net margin
LSAK
LSAK
1.3% more per $
LSAK
2.0%
0.7%
HCM
More free cash flow
HCM
HCM
$18.2M more FCF
HCM
$3.4M
$-14.8M
LSAK

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
HCM
HCM
LSAK
LSAK
Revenue
$270.8M
$178.7M
Net Profit
$2.0M
$3.6M
Gross Margin
37.7%
31.4%
Operating Margin
-13.2%
1.2%
Net Margin
0.7%
2.0%
Revenue YoY
-16.5%
1.4%
Net Profit YoY
-83.6%
111.2%
EPS (diluted)
$0.00
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCM
HCM
LSAK
LSAK
Q4 25
$270.8M
$178.7M
Q3 25
$171.4M
Q2 25
$277.7M
$168.5M
Q1 25
$324.5M
$161.4M
Q4 24
$176.2M
Q3 24
$153.6M
Q2 24
$305.7M
$146.0M
Q1 24
$138.2M
Net Profit
HCM
HCM
LSAK
LSAK
Q4 25
$2.0M
$3.6M
Q3 25
$-4.3M
Q2 25
$455.0M
$-28.4M
Q1 25
$11.9M
$-22.1M
Q4 24
$-32.5M
Q3 24
$-4.5M
Q2 24
$25.8M
$-5.0M
Q1 24
$-4.0M
Gross Margin
HCM
HCM
LSAK
LSAK
Q4 25
37.7%
31.4%
Q3 25
30.9%
Q2 25
0.1%
28.9%
Q1 25
48.0%
27.5%
Q4 24
25.7%
Q3 24
22.6%
Q2 24
41.1%
22.6%
Q1 24
22.0%
Operating Margin
HCM
HCM
LSAK
LSAK
Q4 25
-13.2%
1.2%
Q3 25
0.2%
Q2 25
-1.3%
-16.7%
Q1 25
-5.0%
0.4%
Q4 24
0.3%
Q3 24
-0.0%
Q2 24
-9.0%
0.2%
Q1 24
0.6%
Net Margin
HCM
HCM
LSAK
LSAK
Q4 25
0.7%
2.0%
Q3 25
-2.5%
Q2 25
163.8%
-16.9%
Q1 25
3.7%
-13.7%
Q4 24
-18.4%
Q3 24
-3.0%
Q2 24
8.4%
-3.4%
Q1 24
-2.9%
EPS (diluted)
HCM
HCM
LSAK
LSAK
Q4 25
$0.00
$0.04
Q3 25
$-0.05
Q2 25
$0.52
$-0.40
Q1 25
$0.01
$-0.27
Q4 24
$-0.40
Q3 24
$-0.07
Q2 24
$0.03
$-0.08
Q1 24
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCM
HCM
LSAK
LSAK
Cash + ST InvestmentsLiquidity on hand
$1.4B
$69.5M
Total DebtLower is stronger
$93.2M
$216.8M
Stockholders' EquityBook value
$1.2B
$180.6M
Total Assets
$1.8B
$704.6M
Debt / EquityLower = less leverage
0.08×
1.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCM
HCM
LSAK
LSAK
Q4 25
$1.4B
$69.5M
Q3 25
$72.2M
Q2 25
$1.4B
$76.5M
Q1 25
$836.1M
$71.0M
Q4 24
$60.6M
Q3 24
$49.7M
Q2 24
$802.5M
$59.1M
Q1 24
$55.2M
Total Debt
HCM
HCM
LSAK
LSAK
Q4 25
$93.2M
$216.8M
Q3 25
$208.1M
Q2 25
$93.4M
$200.8M
Q1 25
$82.8M
$194.7M
Q4 24
$148.7M
Q3 24
$148.5M
Q2 24
$82.1M
$143.2M
Q1 24
$135.7M
Stockholders' Equity
HCM
HCM
LSAK
LSAK
Q4 25
$1.2B
$180.6M
Q3 25
$170.4M
Q2 25
$1.2B
$161.6M
Q1 25
$759.9M
$185.2M
Q4 24
$193.3M
Q3 24
$184.2M
Q2 24
$740.1M
$175.9M
Q1 24
$173.1M
Total Assets
HCM
HCM
LSAK
LSAK
Q4 25
$1.8B
$704.6M
Q3 25
$652.9M
Q2 25
$1.8B
$653.7M
Q1 25
$1.3B
$649.2M
Q4 24
$640.6M
Q3 24
$551.9M
Q2 24
$1.3B
$558.5M
Q1 24
$551.5M
Debt / Equity
HCM
HCM
LSAK
LSAK
Q4 25
0.08×
1.20×
Q3 25
1.22×
Q2 25
0.08×
1.24×
Q1 25
0.11×
1.05×
Q4 24
0.77×
Q3 24
0.81×
Q2 24
0.11×
0.81×
Q1 24
0.78×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCM
HCM
LSAK
LSAK
Operating Cash FlowLast quarter
$8.2M
$-10.9M
Free Cash FlowOCF − Capex
$3.4M
$-14.8M
FCF MarginFCF / Revenue
1.2%
-8.3%
Capex IntensityCapex / Revenue
1.8%
2.2%
Cash ConversionOCF / Net Profit
4.21×
-2.99×
TTM Free Cash FlowTrailing 4 quarters
$-96.2M
$-15.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCM
HCM
LSAK
LSAK
Q4 25
$8.2M
$-10.9M
Q3 25
$8.9M
Q2 25
$-72.9M
$-9.1M
Q1 25
$40.3M
$10.7M
Q4 24
$-9.2M
Q3 24
$-4.1M
Q2 24
$-39.8M
$5.7M
Q1 24
$19.2M
Free Cash Flow
HCM
HCM
LSAK
LSAK
Q4 25
$3.4M
$-14.8M
Q3 25
$4.9M
Q2 25
$-82.2M
$-13.2M
Q1 25
$32.5M
$7.8M
Q4 24
$-15.5M
Q3 24
$-8.1M
Q2 24
$-49.9M
$937.0K
Q1 24
$16.2M
FCF Margin
HCM
HCM
LSAK
LSAK
Q4 25
1.2%
-8.3%
Q3 25
2.9%
Q2 25
-29.6%
-7.8%
Q1 25
10.0%
4.9%
Q4 24
-8.8%
Q3 24
-5.3%
Q2 24
-16.3%
0.6%
Q1 24
11.7%
Capex Intensity
HCM
HCM
LSAK
LSAK
Q4 25
1.8%
2.2%
Q3 25
2.3%
Q2 25
3.3%
2.4%
Q1 25
2.4%
1.7%
Q4 24
3.6%
Q3 24
2.6%
Q2 24
3.3%
3.2%
Q1 24
2.1%
Cash Conversion
HCM
HCM
LSAK
LSAK
Q4 25
4.21×
-2.99×
Q3 25
Q2 25
-0.16×
Q1 25
3.38×
Q4 24
Q3 24
Q2 24
-1.54×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCM
HCM

Segment breakdown not available.

LSAK
LSAK

Telecom Products And Services$82.0M46%
Processing Fees$37.6M21%
Enterprise Segment$14.5M8%
Rest Of Africa$10.9M6%
Technology Products$8.6M5%
Insurance Revenue$7.9M4%
Lending Revenue$7.2M4%
Other$6.7M4%
Interest From Customer$2.1M1%
Other Products And Services$1.2M1%

Related Comparisons